Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17808278 | 0.87 | GABRA2 (0.36) | GABRA2GABRB2 | |
| SCHEMBL17816234 | 0.85 | GABRA2 (0.35) | GABRA2GABRB2 | |
| SCHEMBL17816240 | 0.85 | GABRA2 (0.38) | GABRA2GABRB2 | |
| SCHEMBL17808306 | 0.82 | — | — | |
| SCHEMBL29417448 | 0.79 | TDP1 (0.44) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL249075 | 0.79 | TDP1 (0.44) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL10848859 | 0.77 | SMN1; SMN2 (0.33) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL17816259 | 0.77 | GABRA2 (0.31) | GABRA2GABRB2 | |
| SCHEMBL21719163 | 0.76 | KDM4E (0.31) | KDM4EALDH1A1CYP1A2MAPTALOX15 | |
| SCHEMBL5120892 | 0.76 | TDP1 (0.37) | KDM4EALDH1A1CYP1A2MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| EP-3030081-B1 | PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159781-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | KDM4E 953/4885ALDH1A1 300/4885CYP1A2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.